Mankind Pharma Limited Max Pain Analysis

Max Pain Level

The options market for Mankind Pharma Limited (MANKIND) is pinning its highest concentration of open interest at a strike of ₹2,480. Max‑pain theory holds that, as expiry approaches, the underlying price tends to gravitate toward the strike where the aggregate loss for option writers is minimized, creating a magnetic pull on the stock.

Spot vs Max Pain Gap

The current spot price of ₹2,490 sits just ₹10 above the max‑pain level, a narrow +0.4 % premium. This modest gap suggests that the market is either gently testing resistance or that sellers have already positioned to keep the price from slipping further toward the sweet‑spot.

Shift Signal

The max‑pain figure has moved upward by ₹120 from the previous day, indicating that writers have added new exposure at higher strikes. Such a shift typically reflects a defensive stance, as option sellers hedge against a potential upside bias while still hoping the price will settle near the new equilibrium.

Expiry Context

Max‑pain derives from the aggregate payoff structure of all outstanding calls and puts; as time decay accelerates in the final weeks, the incentive to compress price movements intensifies. Historically, the week leading to expiry often exhibits reduced volatility and a tendency for the underlying to converge on the pain point, though this is a statistical tendency rather than a deterministic outcome.

Data Note

With 26 days remaining until the November 23 expiry, the spot price is ₹10 above the max‑pain level, leaving a tight window for any decisive move toward that strike.